Astrazeneca plc ADR (AZN): Not A Time To Panic Nor Freeze

Astrazeneca plc ADR (AZN) concluded trading on Thursday at a closing price of $67.30, with 6.85 million shares of worth about $460.94 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -5.78% during that period and on May 08, 2025 the price saw a loss of about -3.95%. Currently the company’s common shares owned by public are about 3.10B shares, out of which, 3.10B shares are available for trading.

Stock saw a price change of -4.55% in past 5 days and over the past one month there was a price change of 3.70%. Year-to-date (YTD), AZN shares are showing a performance of 2.72% which decreased to -11.17% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $61.24 but also hit the highest price of $87.68 during that period. The average intraday trading volume for Astrazeneca plc ADR shares is 6.09 million. The stock is currently trading -2.48% below its 20-day simple moving average (SMA20), while that difference is down -6.66% for SMA50 and it goes to -8.31% lower than SMA200.

Astrazeneca plc ADR (NASDAQ: AZN) currently have 3.10B outstanding shares and institutions hold larger chunk of about 16.74% of that.

The stock has a current market capitalization of $208.72B and its 3Y-monthly beta is at 0.40. PE ratio of stock for trailing 12 months is 27.04, while it has posted earnings per share of $2.49 in the same period. Its PEG reads 2.42 and has Quick Ratio of 0.70 while making debt-to-equity ratio of 0.77. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AZN, volatility over the week remained 1.84% while standing at 2.46% over the month.

Stock’s fiscal year EPS is expected to rise by 9.64% while it is estimated to increase by 12.93% in next year. EPS is likely to shrink at an annualized rate of 11.16% for next 5-years, compared to annual growth of 34.63% made by the stock over the past 5-years.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Exane BNP Paribas on April 15, 2025 offering an Outperform rating for the stock and assigned a target price of $75 to it. Stock get a Hold rating from Deutsche Bank on November 06, 2024.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.